Nucynta and Dymista drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Nucynta (tapentadol hydrochloride) and Dymista (azelastine hydrochloride; fluticasone propionate). Common drug interactions include chronic kidney disease among females and complex regional pain syndrome among males.

The phase IV clinical study analyzes what interactions people have when they take Nucynta and Dymista. It is created by eHealthMe based on reports of 12 people who take the same drugs from the FDA, and is updated regularly.

What is Nucynta?

Nucynta has active ingredients of tapentadol hydrochloride. It is often used in pain. eHealthMe is studying from 31,818 Nucynta users. Check the latest studies of Nucynta.

What is Dymista?

Dymista has active ingredients of azelastine hydrochloride; fluticasone propionate. It is often used in allergies. eHealthMe is studying from 4,407 Dymista users. Check the latest studies of Dymista.

On Jul, 18, 2026

12 people who take Nucynta and Dymista together, and have interactions are studied.

What are the common drug interactions of Nucynta and Dymista, by gender? *:

female:

Chronic kidney disease
Death
Diverticulitis (digestive disease which involves the formation of pouches (diverticula) within the bowel wall)
Infection parasitic
Irritability
Knee arthroplasty
Oesophageal carcinoma (cancer tumour of oesophagus)
Psoriasis (immune-mediated disease that affects the skin)
Renal impairment (severely reduced kidney function)
Renal injury (kidney injury)

male:

Complex regional pain syndrome (long lasting pain condition most often affecting one of the limbs (arms, legs, hands, or feet))
Cough
Dyspepsia (indigestion)
Abdominal discomfort
Migraine (headache)
Osteopenia (a condition where bone mineral density is lower than normal)
Osteoporosis (bones weak and more likely to break)
Postural orthostatic tachycardia syndrome (abnormal increase in heart rate on becoming upright)
Upper limb fracture

What are the common drug interactions of Nucynta and Dymista, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Psoriasis (immune-mediated disease that affects the skin)

50-59:

Chronic kidney disease
Death
Diverticulitis (digestive disease which involves the formation of pouches (diverticula) within the bowel wall)
Infection parasitic
Oesophageal carcinoma (cancer tumour of oesophagus)
Renal impairment (severely reduced kidney function)
Renal injury (kidney injury)
Tubulointerstitial nephritis (a form of nephritis affecting the interstitium of the kidneys surrounding the tubules)
Urine bilirubin increased

60+:

n/a

What are the existing conditions these people have? *

Complex Regional Pain Syndrome (long lasting pain condition most often affecting one of the limbs (arms, legs, hands, or feet)): 4 people, 33.33%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 2 people, 16.67%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 2 people, 16.67%
Nausea (feeling of having an urge to vomit): 2 people, 16.67%
Dry Mouth: 1 person, 8.33%
High Blood Pressure: 1 person, 8.33%
High Blood Cholesterol: 1 person, 8.33%
Glucose Tolerance Impaired (blood glucose is raised beyond normal levels, but not high enough to warrant a diabetes diagnosis): 1 person, 8.33%
Fungal Infection: 1 person, 8.33%
Food Allergy: 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Nucynta and Dymista?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously